About Dermata Therapeutics, Inc.
http://www.dermatarx.comDermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the treatment of medical and aesthetic skin conditions. The company's lead product candidate is DMT310, a once-weekly topical product that is under clinical development for the treatment of acne vulgaris, psoriasis vulgaris, and papulopustular rosacea.
CEO
Gerald T. Proehl
Compensation Summary
(Year 2024)
Ratings Snapshot
Rating : B-
Price Target
Institutional Ownership
EMPERY ASSET MANAGEMENT, LP
Shares:175K
Value:$4.15K
BOOTHBAY FUND MANAGEMENT, LLC
Shares:12K
Value:$284.4
SUSQUEHANNA INTERNATIONAL GROUP, LLP
Shares:10.18K
Value:$241.17
Summary
Showing Top 3 of 5
About Dermata Therapeutics, Inc.
http://www.dermatarx.comDermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the treatment of medical and aesthetic skin conditions. The company's lead product candidate is DMT310, a once-weekly topical product that is under clinical development for the treatment of acne vulgaris, psoriasis vulgaris, and papulopustular rosacea.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $1.76M ▼ | $-1.69M ▲ | 0% | $-1.65 ▲ | $-1.69M ▲ |
| Q2-2025 | $0 | $1.77M ▼ | $-1.7M ▲ | 0% | $-1.66 ▲ | $-1.7M ▲ |
| Q1-2025 | $0 | $2.34M ▼ | $-2.3M ▲ | 0% | $-4.47 ▲ | $-2.3M ▲ |
| Q4-2024 | $0 | $3.2M ▼ | $-3.15M ▲ | 0% | $-20.4 | $-3.15M ▲ |
| Q3-2024 | $0 | $3.23M | $-3.17M | 0% | $-20.4 | $-3.17M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $4.66M ▼ | $5.07M ▼ | $1.11M ▲ | $3.96M ▼ |
| Q2-2025 | $6.48M ▼ | $6.64M ▼ | $1.03M ▼ | $5.61M ▼ |
| Q1-2025 | $9.72M ▲ | $10.01M ▲ | $2.7M ▲ | $7.3M ▲ |
| Q4-2024 | $3.16M ▼ | $3.53M ▼ | $1.97M ▲ | $1.56M ▼ |
| Q3-2024 | $6.14M | $6.69M | $1.95M | $4.74M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-1.69M ▲ | $-1.8M ▲ | $0 | $-12.99K ▲ | $-1.82M ▲ | $-1.8M ▲ |
| Q2-2025 | $-1.7M ▲ | $-2.69M ▼ | $0 | $-547.86K ▼ | $-3.24M ▼ | $-2.69M ▼ |
| Q1-2025 | $-2.3M ▲ | $-1.93M ▲ | $0 | $8.49M ▲ | $6.56M ▲ | $-1.93M ▲ |
| Q4-2024 | $-3.15M ▲ | $-2.91M ▲ | $0 | $-68.57K ▼ | $-2.98M ▼ | $-2.91M ▲ |
| Q3-2024 | $-3.17M | $-3.42M | $0 | $4.62M | $1.2M | $-3.42M |
CEO
Gerald T. Proehl
Compensation Summary
(Year 2024)
Ratings Snapshot
Rating : B-
Price Target
Institutional Ownership
EMPERY ASSET MANAGEMENT, LP
Shares:175K
Value:$4.15K
BOOTHBAY FUND MANAGEMENT, LLC
Shares:12K
Value:$284.4
SUSQUEHANNA INTERNATIONAL GROUP, LLP
Shares:10.18K
Value:$241.17
Summary
Showing Top 3 of 5